Lymphoma immunotherapy: current status

Lymphoma immunotherapy: current status

The rationale to treat lymphomas with immunotherapy comes from long-standing evidence on their distinctive immune responsiveness. Indolent B-cell non-Hodgkin lymphomas (B-NHLs), in particular, establish key interactions with the immune microenvironment to ensure prosurvival signals and prevent antit...

Full description

Bibliographic Details
Main Authors: Roberta eZappasodi, Filippo eDe Braud, Massimo eDi Nicola
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-09-01
Series:Frontiers in Immunology
Subjects:
Dendritic Cells
Immunotherapy
Tumor-associated antigens
adaptive immune response
B-cell lymphoma
Anticancer vaccines
Online Access:http://journal.frontiersin.org/Journal/10.3389/fimmu.2015.00448/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fimmu.2015.00448/full

Similar Items